• 13980 Citations
  • 64 h-Index
1993 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Platinum Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Endometrial Neoplasms Medicine & Life Sciences
Uterine Cervical Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1993 2019

Alisertib in Combination with Weekly Paclitaxel in Patients with Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial

Falchook, G., Coleman, R., Roszak, A., Behbakht, K., Matulonis, U., Ray-Coquard, I., Sawrycki, P., Duska, L. R., Tew, W., Ghamande, S., Lesoin, A., Schwartz, P. E., Buscema, J., Fabbro, M., Lortholary, A., Goff, B., Kurzrock, R., Martin, L. P., Gray, H. J., Fu, S. & 6 othersSheldon-Waniga, E., Lin, H. M., Venkatakrishnan, K., Zhou, X., Leonard, E. J. & Schilder, R. J., Jan 1 2019, In : JAMA Oncology. 5, 1

Research output: Contribution to journalArticle

Paclitaxel
Ovarian Neoplasms
Randomized Controlled Trials
Breast Neoplasms
Disease-Free Survival

A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS)

Slomovitz, B. M., Taub, M. C., Huang, M., Levenback, C. F. & Coleman, R., Feb 1 2019, In : Gynecologic Oncology Reports. 27, p. 1-4 4 p.

Research output: Contribution to journalArticle

letrozole
Leiomyosarcoma
Observation

Exploring and comparing adverse events between PARP inhibitors

LaFargue, C. J., Dal Molin, G. Z., Sood, A. K. & Coleman, R., Jan 1 2019, In : The lancet oncology. 20, 1, p. e15-e28

Research output: Contribution to journalReview article

Ovarian Neoplasms
Recombinational DNA Repair
Poisons
United States Food and Drug Administration
Pharmaceutical Preparations
Ovarian Neoplasms
Neoplasms
cyhalothrin

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice

Jazaeri, A. A., Coleman, R., Sood, A. K., Frumovitz, M., Soliman, P. T., Shafer, A., Cutrera, J. J., Klinger, M., Sharafi, S. E., Johnson, C. A. L., Villanueva, V. F., Hinchcliff, E. M., Dickens, A., Cain, K. E., Anderson, J. E., Lu, K. H. & Westin, S. N., Nov 1 2018, In : Gynecologic oncology. 151, 2, p. 374-380 7 p.

Research output: Contribution to journalReview article

Immunotherapy
Pharmaceutical Preparations
Neoplasms
Therapeutics
Clinical Trials